TRAMADOL HYDROCHLORIDE Drug Interactions
Also known as: TRAMADOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE (brand name: TRAMADOL HYDROCHLORIDE) is a Opioid Analgesics. 1 INDICATIONS AND USAGE Tramadol hydrochloride tablets are indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can…TRAMADOL HYDROCHLORIDE has 17 documented drug interactions in our database, including 9 contraindicated, 8 major, 0 moderate, and 0 minor interactions.
9
Contraindicated
8
Major
0
Moderate
0
Minor
This combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased respiratory rate, shallow breathing, hypoxemia, unresponsiveness, and difficulty arousing.
Mechanism
Both tramadol, an opioid analgesic, and lorazepam, a benzodiazepine, are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, particularly on the respiratory drive and level of consciousness, by enhancing GABAergic neurotransmission and opioid receptor agonism, respectively.
Clinical Management
Concomitant use of opioids and benzodiazepines should generally be avoided due to the FDA Black Box Warning. If co-administration is absolutely necessary and no alternatives exist, use the lowest effective doses for the shortest possible duration, closely monitor patients for respiratory depression and sedation, and educate patients and caregivers on the risks. Naloxone should be readily available.
The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may exhibit decreased level of consciousness, hypoventilation, pinpoint pupils, and hypotension.
Mechanism
Both tramadol, an opioid analgesic, and clonazepam, a benzodiazepine, are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, particularly on the respiratory drive, mediated through distinct but synergistic pathways.
Clinical Management
Concomitant use is contraindicated due to the high risk of severe adverse outcomes. If co-administration is unavoidable, prescribe the lowest effective doses for the shortest duration possible, and closely monitor for respiratory depression and sedation. Consider naloxone availability and patient education on risk factors.
The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may exhibit decreased level of consciousness, hypoventilation, bradycardia, hypotension, and miosis. These effects can be life-threatening and require immediate medical intervention.
Mechanism
Tramadol, an opioid analgesic, and diazepam, a benzodiazepine, both exert central nervous system (CNS) depressant effects. Tramadol's actions are primarily mediated through mu-opioid receptor agonism and inhibition of norepinephrine and serotonin reuptake, while diazepam enhances the effect of the inhibitory neurotransmitter GABA at the GABA-A receptor. Concomitant use leads to an additive and synergistic depression of the CNS, particularly affecting respiratory drive.
Clinical Management
Concomitant use of tramadol and diazepam is generally contraindicated due to the severe risks. If co-administration is unavoidable, it should be reserved for patients for whom alternative treatment options are inadequate, and the lowest effective doses should be used for the shortest possible duration. Patients must be closely monitored for signs of respiratory depression and sedation, and naloxone should be readily available.
The combination of tramadol and alprazolam can lead to profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypotension, and psychomotor impairment. This interaction significantly increases the risk of accidental overdose and life-threatening respiratory events.
Mechanism
Tramadol, an opioid analgesic, and alprazolam, a benzodiazepine, both exert central nervous system (CNS) depressant effects. Opioids primarily activate mu-opioid receptors, leading to analgesia and respiratory depression, while benzodiazepines enhance the effect of the inhibitory neurotransmitter GABA at GABA-A receptors, resulting in sedation and anxiolysis. The co-administration of these agents leads to an additive and synergistic depression of the CNS, significantly increasing the risk of severe adverse outcomes.
Clinical Management
Concomitant use of tramadol and alprazolam is contraindicated due to the high risk of respiratory depression and death, as highlighted by an FDA Black Box Warning. If co-administration is unavoidable, the lowest effective doses should be used for the shortest possible duration, and patients must be closely monitored for signs of respiratory depression and sedation. Consider alternative non-opioid or non-benzodiazepine therapies, or taper one or both medications if already on combination therapy.
Concomitant use can lead to profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, hypotension, and psychomotor impairment. Even at usual doses, the combination can be life-threatening.
Mechanism
Tramadol is an opioid analgesic that binds to mu-opioid receptors, inhibiting pain transmission and causing central nervous system (CNS) depression. Oxazepam is a benzodiazepine that enhances the effect of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, leading to further CNS depression. The synergistic CNS depressant effects of both drugs significantly increase the risk of severe adverse outcomes.
Clinical Management
Due to the severe and potentially fatal risks, co-prescription of tramadol and oxazepam is contraindicated. If alternative therapies are not feasible, and the combination is deemed absolutely necessary, prescribe the lowest effective doses for the shortest possible duration, and closely monitor for respiratory depression and sedation. Educate patients and caregivers on the risks and symptoms of CNS depression.
Patients may experience profound sedation, respiratory depression (including apnea), hypotension, psychomotor impairment, coma, and death. The combination significantly increases the risk of accidental overdose and life-threatening adverse events. Impaired cognitive function and motor coordination can also increase the risk of falls and other injuries.
Mechanism
Tramadol, an opioid analgesic, and temazepam, a benzodiazepine, both cause central nervous system (CNS) depression. The co-administration of these agents leads to an additive depressant effect on the CNS, primarily affecting respiratory drive and consciousness. This synergistic effect is due to their distinct but converging actions on GABA-A receptors (benzodiazepines) and opioid receptors (opioids), leading to profound suppression of neural activity.
Clinical Management
Concomitant use of tramadol and temazepam is generally contraindicated due to the high risk of severe adverse outcomes, including respiratory depression and death. If no alternative treatments are adequate, and the benefits outweigh the risks, prescribe the lowest effective doses for the shortest possible duration, and closely monitor patients for signs of respiratory depression and sedation. Educate patients and caregivers about the risks and symptoms to watch for, and ensure naloxone is available if indicated.
Patients may experience severe respiratory depression, potentially leading to respiratory arrest, hypoxia, and death. Other clinical effects include profound sedation, somnolence, coma, hypotension, psychomotor impairment, and increased risk of accidental overdose or injury.
Mechanism
Tramadol, an opioid analgesic, and triazolam, a benzodiazepine, both depress the central nervous system (CNS). Opioids primarily act on mu-opioid receptors, while benzodiazepines enhance the effects of gamma-aminobutyric acid (GABA) at GABA-A receptors. The synergistic CNS depressant effects of these two drug classes lead to profound respiratory depression, sedation, and hypotension.
Clinical Management
Concomitant use of tramadol and triazolam is generally contraindicated due to the high risk of serious adverse outcomes, including respiratory depression and death. If no alternative treatments are available and co-prescription is absolutely necessary, use the lowest effective doses for the shortest possible duration, monitor patients closely for respiratory depression and sedation, and provide naloxone for opioid overdose reversal. Educate patients and caregivers on the risks and symptoms of respiratory depression.
Concomitant use can cause severe respiratory depression, profound sedation, hypotension, psychomotor impairment, coma, and death. Patients may exhibit decreased level of consciousness, bradycardia, hypoventilation, and cyanosis.
Mechanism
Both tramadol (an opioid analgesic) and midazolam (a benzodiazepine) are central nervous system (CNS) depressants. Their coadministration leads to additive pharmacodynamic effects, significantly enhancing GABAergic inhibition and mu-opioid receptor agonism, resulting in profound CNS and respiratory depression.
Clinical Management
The coadministration of tramadol and midazolam is contraindicated due to the high risk of severe adverse outcomes, including respiratory depression and death. If no alternative treatments are available and coadministration is deemed absolutely necessary, prescribe the lowest effective doses and shortest durations, monitor patients closely for respiratory depression and sedation, and provide naloxone and flumazenil availability.
The combination significantly increases the risk of profound sedation, respiratory depression, coma, and death. Patients may experience extreme drowsiness, confusion, dizziness, slowed or difficult breathing, and unresponsiveness.
Mechanism
Both tramadol (an opioid analgesic) and chlordiazepoxide (a benzodiazepine) are central nervous system (CNS) depressants. Their co-administration leads to additive CNS depression, primarily by enhancing gamma-aminobutyric acid (GABA)ergic neurotransmission (benzodiazepine) and acting on opioid receptors (tramadol), resulting in synergistic effects on respiratory and CNS function.
Clinical Management
Concomitant use of tramadol and chlordiazepoxide should be avoided. If alternative treatments are not adequate, and co-prescription is absolutely necessary, the lowest effective doses should be used for the shortest possible duration, and patients must be closely monitored for respiratory depression and sedation. Prescribers should warn patients and caregivers of these risks.
Patients may experience profound sedation, dizziness, confusion, and impaired psychomotor function. There is an increased risk of respiratory depression, potentially leading to hypoventilation or apnea, and an elevated risk of falls and accidental injury.
Mechanism
Both tramadol and cyclobenzaprine exert central nervous system (CNS) depressant effects. Tramadol acts as a weak opioid agonist and also inhibits norepinephrine and serotonin reuptake, while cyclobenzaprine is a centrally acting skeletal muscle relaxant with anticholinergic properties. The co-administration leads to an additive pharmacological effect on CNS depression.
Clinical Management
Concomitant use should generally be avoided due to the significant risk of additive CNS depression. If co-administration is unavoidable, initiate both medications at the lowest effective doses and monitor patients closely for signs of respiratory depression, sedation, and mental status changes. Educate patients about the risks and advise against operating machinery or driving.
Patients may experience increased sedation, dizziness, confusion, and psychomotor impairment. The most serious clinical effect is an elevated risk of respiratory depression, which can be life-threatening. This combination can also significantly impair the ability to operate machinery or drive.
Mechanism
Both tramadol and methocarbamol exert central nervous system (CNS) depressant effects. Tramadol's mechanism involves opioid receptor agonism and inhibition of norepinephrine and serotonin reuptake, while methocarbamol acts as a general CNS depressant. The co-administration leads to an additive depressant effect on the CNS.
Clinical Management
Concomitant use should be avoided if possible. If co-administration is necessary, use the lowest effective doses for the shortest duration, and monitor patients closely for signs of CNS and respiratory depression. Educate patients about the risks and advise against activities requiring mental alertness.
Patients may experience profound sedation, dizziness, confusion, and psychomotor impairment. There is an increased risk of respiratory depression, which can be life-threatening, and hypotension. Impaired motor function can lead to an increased risk of falls and accidents.
Mechanism
Both tramadol and carisoprodol are central nervous system (CNS) depressants. Tramadol exerts its analgesic effects primarily through mu-opioid receptor agonism and inhibition of norepinephrine and serotonin reuptake. Carisoprodol is a centrally acting skeletal muscle relaxant that is metabolized to meprobamate, a Schedule IV controlled substance with anxiolytic and sedative properties. The concomitant use leads to an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of tramadol and carisoprodol due to the significant risk of additive CNS depression. If co-administration is unavoidable, reduce the dosage of one or both drugs, monitor patients closely for signs of respiratory depression and sedation, and educate them on the risks. Consider alternative non-opioid analgesics or non-benzodiazepine muscle relaxants.
Patients may experience profound sedation, respiratory depression, hypotension, and impaired psychomotor function. This can lead to an increased risk of falls, accidental injury, and potentially life-threatening respiratory compromise. Symptoms may include extreme drowsiness, confusion, dizziness, shallow breathing, and unresponsiveness.
Mechanism
Tramadol, an opioid analgesic, primarily exerts its effects through mu-opioid receptor agonism and inhibition of norepinephrine and serotonin reuptake. Baclofen, a skeletal muscle relaxant, acts as a GABA-B receptor agonist in the spinal cord. The concomitant use of these agents results in additive central nervous system (CNS) depression.
Clinical Management
Avoid concomitant use if possible. If co-administration is necessary, initiate both medications at the lowest effective doses and titrate slowly, closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise them to avoid driving or operating heavy machinery. Consider alternative therapies if the risk outweighs the benefits.
Patients may experience profound sedation, dizziness, confusion, and impaired psychomotor function. This additive CNS depression significantly increases the risk of respiratory depression, hypotension, and falls. In severe cases, it can lead to coma or death.
Mechanism
Both tramadol and tizanidine cause central nervous system (CNS) depression. Tramadol exerts its analgesic effect through opioid receptor agonism and inhibition of norepinephrine and serotonin reuptake, contributing to CNS depression. Tizanidine is an alpha-2 adrenergic agonist that reduces spasticity by increasing presynaptic inhibition of motor neurons in the spinal cord, also leading to significant CNS depression. The concurrent use results in an additive depressant effect on the CNS.
Clinical Management
Avoid concurrent use of tramadol and tizanidine if possible. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate cautiously while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise against operating machinery or driving until the effects are known.
Patients may experience profound sedation, respiratory depression, hypotension, dizziness, and impaired psychomotor function. This combination significantly increases the risk of falls, accidental injury, and potentially life-threatening respiratory compromise.
Mechanism
Both tramadol and metaxalone exert central nervous system (CNS) depressant effects. Tramadol acts as a weak opioid agonist and also inhibits the reuptake of norepinephrine and serotonin, while metaxalone's muscle relaxant properties are attributed to general CNS depression. The co-administration leads to an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of tramadol and metaxalone if possible. If co-administration is unavoidable, initiate treatment with the lowest effective doses of both medications and monitor patients closely for signs of CNS depression, particularly during treatment initiation or dose escalation. Educate patients about the risks and advise against operating machinery or driving.
Patients may experience increased drowsiness, dizziness, confusion, and psychomotor impairment. There is a significant risk of respiratory depression, which can be life-threatening, and profound sedation that may impair the ability to operate machinery or perform other hazardous tasks.
Mechanism
Both tramadol, an opioid analgesic, and chlorzoxazone, a centrally acting muscle relaxant, produce central nervous system (CNS) depression. The co-administration of these agents results in an additive depressant effect on the CNS, leading to enhanced sedation and respiratory depression.
Clinical Management
Concomitant use should be avoided if possible. If co-administration is necessary, initiate with the lowest effective doses of both medications and monitor patients closely for signs of CNS and respiratory depression. Educate patients about the risks and advise against driving or operating heavy machinery.
Patients may experience profound sedation, respiratory depression, hypotension, and psychomotor impairment. This can increase the risk of falls, accidents, and life-threatening respiratory compromise. Symptoms of anticholinergic toxicity such as confusion, delirium, and urinary retention may also be exacerbated.
Mechanism
Tramadol is an opioid analgesic that primarily acts on mu-opioid receptors and also inhibits reuptake of norepinephrine and serotonin. Orphenadrine is a skeletal muscle relaxant with anticholinergic and antihistaminic properties that contributes to central nervous system (CNS) depression. The co-administration of these agents leads to an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of tramadol and orphenadrine if possible. If co-administration is unavoidable, reduce the starting dose of one or both medications, particularly in elderly or debilitated patients. Monitor patients closely for signs of respiratory depression, excessive sedation, and altered mental status, and advise them against operating heavy machinery or driving.
For complete prescribing information:
View full TRAMADOL HYDROCHLORIDE monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.